Amidst geopolitical tensions and economic uncertainties, European markets have faced a challenging environment, with the STOXX Europe 600 Index experiencing a decline of 1.79% recently. In this context, identifying growth companies with high insider ownership can be particularly appealing to investors seeking resilience and potential upside in volatile conditions.
Top 10 Growth Companies With High Insider Ownership In Europe
| Name | Insider Ownership | Earnings Growth |
| Kuros Biosciences (SWX:KURN) | 26.1% | 58.4% |
| KebNi (OM:KEBNI B) | 11.8% | 90.9% |
| Hacksaw (OM:HACK) | 13.2% | 24.8% |
| Dellia Group (OB:DELIA) | 29.9% | 47.9% |
| CTT Systems (OM:CTT) | 17.4% | 47.1% |
| Clavister Holding AB (publ.) (OM:CLAV) | 20.7% | 73.9% |
| Circus (XTRA:CA1) | 21.9% | 84.4% |
| CD Projekt (WSE:CDR) | 35.2% | 29.7% |
| Bonesupport Holding (OM:BONEX) | 10.6% | 33.7% |
| Bergen Carbon Solutions (OB:BCS) | 11.9% | 50.2% |
Let's explore several standout options from the results in the screener.
Egetis Therapeutics (OM:EGTX)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Egetis Therapeutics AB (publ) is a pharmaceutical company focused on the development and commercialization of orphan drugs in Sweden and internationally, with a market capitalization of SEK2.83 billion.
Operations: Egetis Therapeutics AB generates revenue primarily from its Emcitate segment, amounting to SEK63.10 million.
Insider Ownership: 18.4%
Earnings Growth Forecast: 56.4% p.a.
Egetis Therapeutics is positioned for substantial growth, with revenue expected to increase by 36.9% annually, outpacing the Swedish market. Despite a net loss of SEK 94.5 million in Q1 2026 and recent shareholder dilution from a SEK 350 million equity offering, the company anticipates profitability within three years. Recent board appointments and presentations at major conferences highlight its strategic focus on expansion and innovation in therapeutic solutions.
- Unlock comprehensive insights into our analysis of Egetis Therapeutics stock in this growth report.
- Our expertly prepared valuation report Egetis Therapeutics implies its share price may be too high.
Metall Zug (SWX:METN)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Metall Zug AG operates through its subsidiaries in medical devices, infection control, technology cluster and infrastructure, serving markets in Switzerland and internationally, with a market cap of CHF324.75 million.
Operations: The company's revenue segments include Medical Devices generating CHF158.55 million, Investments & Corporate contributing CHF34.50 million, and Technology Cluster & Infrastructure adding CHF1.58 million.
Insider Ownership: 35.8%
Earnings Growth Forecast: 97.5% p.a.
Metall Zug is poised for growth, with earnings projected to rise 97.48% annually, surpassing average market expectations. While revenue growth at 6.7% per year lags behind the desired 20%, it still exceeds the Swiss market's rate of 4.9%. Despite a low forecasted return on equity of 1.8% in three years and no recent insider trading activity, its strategic decision to retain earnings rather than distribute dividends reflects a focus on long-term expansion.
- Dive into the specifics of Metall Zug here with our thorough growth forecast report.
- Our comprehensive valuation report raises the possibility that Metall Zug is priced higher than what may be justified by its financials.
Deutsche Beteiligungs (XTRA:DBAN)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Deutsche Beteiligungs AG is a private equity and venture capital firm headquartered in Frankfurt am Main, Germany, with a market cap of €376.82 million.
Operations: The firm's revenue segments include Fund Investment Services generating €49.01 million and Private Equity Investments contributing €1.12 billion.
Insider Ownership: 31.1%
Earnings Growth Forecast: 52.1% p.a.
Deutsche Beteiligungs AG faces challenges with a recent net loss of €20.46 million, yet it shows potential for growth. Revenue is forecast to grow at 22.8% annually, outpacing the German market's 6.7%. Despite trading at 43.4% below fair value estimates and having a low return on equity forecast of 6.7%, analysts expect profitability within three years, suggesting an opportunity for recovery and expansion despite current financial setbacks.
- Click here to discover the nuances of Deutsche Beteiligungs with our detailed analytical future growth report.
- The analysis detailed in our Deutsche Beteiligungs valuation report hints at an deflated share price compared to its estimated value.
Taking Advantage
- Unlock more gems! Our Fast Growing European Companies With High Insider Ownership screener has unearthed 206 more companies for you to explore.Click here to unveil our expertly curated list of 209 Fast Growing European Companies With High Insider Ownership.
- Want To Explore Some Alternatives? Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com